🇺🇸 FDA
Patent

US 10865236

Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof

granted A61KA61K2039/505A61K2039/572

Quick answer

US patent 10865236 (Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K2039/572, A61K39/40, A61P